A Phase 3 interventional study of Romosozumab and Placebo in Osteoporosis, sponsored by UCB Biopharma SRL. Completed at 30 sites in China. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Zhenlin Z, Qingyun X, Decai C, Aijun C, Yanan H, Mei Z, Xu C, Hua L, Youjia X, Qun C, Huilin Y, Xiaoyan X, Yujie L, Xuan D, Jun J, LingLing G, Theresa RJ, Lars…PubMed 42282279 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.
Among the 20 studies testing romosozumab in Osteoporosis, this one is the 3rd largest by enrollment, is one of 5 that started in 2021, is one of 5 in phase 3, and was the 11th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
University of Aarhus · Sites in Denmark
Ages 50+ · Women only
Sahlgrenska University Hospital · Sites in Sweden
Ages 60+ · Women only
Tuen Mun Hospital · Sites in Hong Kong
Ages 18+
Marmara University · Sites in Turkey
Ages 55–85 · Women only
By country, each count listing its studies:
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2021.
This study's enrollment of 327 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 80 across the 20 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing romosozumab in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07757373Tuen Mun HospitalRomosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing romosozumab in Osteoporosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must have at least 1 of following independent risk factors for fracture:
Exclusion Criteria:
Subject has used oral bisphosphonates:
Subject has used intravenous (iv) bisphosphonates:
zoledronic acid
iv ibandronate, iv pamidronate, or iv alendronate (ALN)
Subject has used denosumab or any cathepsin K inhibitor:
● Any doses received within 18 months prior to randomization
Subject has used tibolone, cinacalcet, or calcitonin:
Subject has used teriparatide (TPTD) or any parathyroid hormone (PTH) derivative:
Subject has used systemic oral or transdermal estrogen or selective estrogen receptor modulators (SERMs):
● More than 1 month of cumulative use within 6 months prior to randomization
Subject has used strontium ranelate or fluoride:
● More than 1 month of cumulative use within 5 years prior to randomization
Subject has used hormonal ablation therapy:
● More than 1 month of cumulative use within 6 months prior to randomization
Subject has used systemic glucocorticosteroids:
● ≥5mg prednisone equivalent per day for more than 14 days within 3 months prior to randomization
Subject has evidence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive romosozumab during all treatment Periods.
Drug: Romosozumab
Subjects randomized to this arm will receive placebo during the Double-Blind-Placebo controlled Period and romosozumab during the Open-Label treatment Period
Drug: Romosozumab · Drug: Placebo
Subjects will receive romosozumab in a specified sequence during the treatment Period.
Subjects will receive Placebo in a specified sequence during the treatment Period.
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period
Percent change from baseline in BMD at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA) at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the last observation carried forward (LOCF) approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. LSM = least square mean.
Time frame: From Baseline (Day 1) to the end of the Double-blind Period (Month 6)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a IMP, whether or not related to the IMP. TEAEs are defined as all AEs started on or worsened in severity on or after the date of receiving first dose of IMP and before or on the end of study (EOS) date.
Time frame: From Baseline to the end of the Double-blind Period (Month 6)
Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with use of a IMP, whether or not related to IMP. TEAEs are defined as all AEs started on or worsened in severity on or after date of receiving first dose of IMP and before or on EOS date except lipid-type AEs starting on date of first dose of IMP and not worsening (and not deemed IMP related by the investigator). As pre-specified in Protocol and SAP, TEAEs were assessed and reported for 6 months for participants in placebo/romosozumab arm (Open-label Period) and for a total of 12 months for participants in romosozumab/romosozumab arm (Double-blind Period + Open-label Period combined) + 3 months of Safety follow-up for both arms (Up to Month 15) during overall period.
Time frame: From Month 7 up to Month 12 (Placebo/Romo) and From Day 1 up to Month 12 (Romo/Romo) + 3-month SFU (up to Month 15)
Percent Change From Baseline in Bone Mineral Density at the Total Hip to the End of Double-Blind Period
Percent change from baseline in BMD at the total hip was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.
Time frame: From Baseline to the end of the Double-blind Period (Month 6)
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck to the End of the Double-Blind Period
Percent change from baseline in BMD at the femoral neck was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.
Time frame: From Baseline to the end of the Double-blind Period (Month 6)
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12
Percent change from Baseline in BMD at the lumbar spine was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.
Time frame: Baseline, Month 12
Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12
Percent change from Baseline in BMD at the total hip was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.
Time frame: Baseline, Month 12
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12
Percent change from Baseline in BMD at the femoral neck was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.
Time frame: Baseline, Month 12
The study started to enroll participants in October 2021 and concluded in November 2023.
| Milestone | Placebo | Romosozumab | Placebo/Romosozumab | Romosozumab/Romosozumab |
|---|---|---|---|---|
| Started | 109 | 218 | 0 | 0 |
| Completed | 100 | 204 | 0 | 0 |
| Not completed | 9 | 14 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 10 | 0 | 0 |
| Withdrew: Patient voluntary withdrawal | 1 | 0 | 0 | 0 |
| Withdrew: The patient withdrew early due to their own reasons | 0 | 1 | 0 | 0 |
| Milestone | Placebo | Romosozumab | Placebo/Romosozumab | Romosozumab/Romosozumab |
|---|---|---|---|---|
| Started | 0 | 0 | 99 | 204 |
| Completed | 0 | 0 | 93 | 199 |
| Not completed | 0 | 0 | 6 | 5 |
| Withdrew: Adverse event | 0 | 0 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
| Withdrew: Subject was unable to comply with study procedures due to prolonged withdrawal from medication | 0 | 0 | 1 | 0 |
| Withdrew: Did not receive open-label imp at month 6 and then discontinued | 0 | 0 | 1 | 0 |
Percent change from baseline in BMD at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA) at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the last observation carried forward (LOCF) approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. LSM = least square mean.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period | 0.44 ± 0.442 | 9.81 ± 0.323 |
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a IMP, whether or not related to the IMP. TEAEs are defined as all AEs started on or worsened in severity on or after the date of receiving first dose of IMP and before or on the end of study (EOS) date.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | 70.6 | 72.9 |
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with use of a IMP, whether or not related to IMP. TEAEs are defined as all AEs started on or worsened in severity on or after date of receiving first dose of IMP and before or on EOS date except lipid-type AEs starting on date of first dose of IMP and not worsening (and not deemed IMP related by the investigator). As pre-specified in Protocol and SAP, TEAEs were assessed and reported for 6 months for participants in placebo/romosozumab arm (Open-label Period) and for a total of 12 months for participants in romosozumab/romosozumab arm (Double-blind Period + Open-label Period combined) + 3 months of Safety follow-up for both arms (Up to Month 15) during overall period.
| percentage of participants | Placebo/Romosozumab | Romosozumab/Romosozumab Overall |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period | 80.6 | 88.1 |
Percent change from baseline in BMD at the total hip was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Total Hip to the End of Double-Blind Period | 0.07 ± 0.285 | 2.93 ± 0.206 |
Percent change from baseline in BMD at the femoral neck was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Femoral Neck to the End of the Double-Blind Period | -0.15 ± 0.406 | 3.33 ± 0.347 |
Percent change from Baseline in BMD at the lumbar spine was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.
| percent change | Placebo/Romosozumab Overall | Romosozumab/Romosozumab Overall |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12 | 8.80 ± 0.554 | 13.04 ± 0.389 |
Percent change from Baseline in BMD at the total hip was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.
| percent change | Placebo/Romosozumab Overall | Romosozumab/Romosozumab Overall |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12 | 1.83 ± 0.306 | 4.22 ± 0.216 |
Percent change from Baseline in BMD at the femoral neck was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.
| percent change | Placebo/Romosozumab Overall | Romosozumab/Romosozumab Overall |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12 | 1.87 ± 0.441 | 4.66 ± 0.371 |
Collected over From Baseline to Safety Follow Up (up to Month 15). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/109 (0%) | 5/109 (4.6%) | 25/109 (22.9%) |
| Romosozumab | 0/218 (0%) | 8/218 (3.7%) | 59/218 (27.1%) |
| Placebo/Romosozumab | 0/98 (0%) | 9/98 (9.2%) | 59/98 (60.2%) |
| Romosozumab/Romosozumab Overall | 1/218 (0.5%) | 25/218 (11.5%) | 155/218 (71.1%) |
| Event | Placebo | Romosozumab | Placebo/Romosozumab | Romosozumab/Romosozumab Overall |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/109 | 0/218 | 1/98 | 0/218 |
| Upper respiratory tract infectionInfections and infestations | 0/109 | 0/218 | 1/98 | 0/218 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/109 | 0/218 | 1/98 | 0/218 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/109 | 0/218 | 1/98 | 1/218 |
| Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/109 | 0/218 | 1/98 | 0/218 |
| Cerebrovascular insufficiencyNervous system disorders | 0/109 | 0/218 | 1/98 | 2/218 |
| Diabetic neuropathyNervous system disorders | 0/109 | 0/218 | 1/98 | 0/218 |
| Lacunar infarctionNervous system disorders | 0/109 | 0/218 | 1/98 | 0/218 |
| Vertebrobasilar insufficiencyNervous system disorders | 0/109 | 0/218 | 1/98 | 0/218 |
| Calculus urinaryRenal and urinary disorders | 0/109 | 0/218 | 1/98 | 0/218 |
| Event | Placebo | Romosozumab | Placebo/Romosozumab | Romosozumab/Romosozumab Overall |
|---|---|---|---|---|
| COVID-19Infections and infestations | 12/109 | 15/218 | 22/98 | 49/218 |
| Suspected COVID-19Infections and infestations | 4/109 | 11/218 | 14/98 | 43/218 |
| Upper respiratory tract infectionInfections and infestations | 5/109 | 13/218 | 6/98 | 30/218 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/109 | 6/218 | 12/98 | 19/218 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/109 | 11/218 | 1/98 | 22/218 |
| Injection site reactionGeneral disorders | 1/109 | 19/218 | 6/98 | 20/218 |
| PyrexiaGeneral disorders | 1/109 | 3/218 | 6/98 | 16/218 |
| Back painMusculoskeletal and connective tissue disorders | 3/109 | 8/218 | 1/98 | 16/218 |
| SARS-CoV-2 test positiveInvestigations | 1/109 | 3/218 | 3/98 | 12/218 |
| HyperlipidaemiaMetabolism and nutrition disorders | 2/109 | 9/218 | 4/98 | 12/218 |
Baseline Characteristics refer to the RS which consisted of study participants who were randomized into this study.
| Age, Continuous(Years) | Placebo | Romosozumab | Total |
|---|---|---|---|
| Mean | 67.3 ± 6.1 | 67.0 ± 5.7 | 67.1 ± 5.8 |
| Age, Customized(Participants) | Placebo | Romosozumab | Total |
|---|---|---|---|
| 18 - <65 yrs | 31 | 63 | 94 |
| 65 - <85 yrs | 76 | 154 | 230 |
| >=85 yrs | 2 | 1 | 3 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab | Total |
|---|---|---|---|
| Female | 109 | 218 | 327 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab | Total |
|---|---|---|---|
| Asian | 109 | 218 | 327 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab | Total |
|---|---|---|---|
| Not Hispanic or Latino | 109 | 218 | 327 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · vivli.org
Ran from Oct 2021 to primary completion in Nov 2023, 24 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 24 months is close to that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Zhenlin Z, Qingyun X, Decai C, Aijun C, Yanan H, Mei Z, Xu C, Hua L, Youjia X, Qun C, Huilin Y, Xiaoyan X, Yujie L, Xuan D, Jun J, LingLing G, Theresa RJ, Lars…PubMed 42282279 ↗
Zhenlin Z, Qingyun X, Decai C, Aijun C, Yanan H, Mei Z, Xu C, Hua L, Youjia X, Qun C, Huilin Y, Xiaoyan X, Yujie L, Xuan D, Jun J, LingLing G, Theresa RJ, Lars…PubMed 42282279 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab